57 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
CTMX CytomX Therapeutics, Inc. $18.52 $832.73M Downtrend
Article Searches
CytomX Therapeutics' (CTMX) CEO Sean McCarthy on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4244999-cytomx-therapeutics-ctmx-ceo-sean-mccarthy-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Feb 27, 2019 - CytomX Therapeutics (NASDAQ:CTMX) Q4 2018 Earnings Conference Call February 27, 2019, 5:00 pm ET Company Participants Chris Keenan - VP, IR Sean McCarthy - President, CEO & Chairman Debanjan Ray -
Analysts Estimate CytomX Therapeutics (CTMX) to Report a Decline in Earnings: What to Look Out for http://www.zacks.com/stock/news/355756/analysts-estimate-cytomx-therapeutics-ctmx-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-ZC-FT-355756 Feb 20, 2019 - CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CytomX' Translational Data On CX-072 Point Towards A Positive Readout From CX-2009 https://seekingalpha.com/article/4222467-cytomx-translational-data-cxminus-072-point-towards-positive-readout-cxminus-2009?source=feed_tag_editors_picks Nov 15, 2018 -
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q3 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4221092-cytomx-therapeutics-inc-ctmx-ceo-sean-mccarthy-q3-2018-results-earnings-call-transcript?source=feed_sector_healthcare Nov 11, 2018 - Start Time: 17:00 End Time: 17:34 CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2018 Earnings Conference Call November 06, 2018, 17:00 PM ET Executives Sean McCarthy - President and CEO Debanjan Ray - CF
Playing The Expectations Game In Biotech https://seekingalpha.com/article/4187892-playing-expectations-game-biotech?source=feed_all_articles Jul 17, 2018 - The biotechnology sector is fertile ground for highly profitable investments, but the downside risk in the sector is also above average.Since the dispersion in returns is so wide, picking the right in
CytomX Therapeutics announces pricing of common stock https://seekingalpha.com/news/3369861-cytomx-therapeutics-announces-pricing-common-stock?source=feed_news_all Jul 13, 2018 - CytomX Therapeutics (NASDAQ:CTMX) priced public offering of 5.10M common at $24.50/share for gross proceeds of $125M.Underwriters have a 30-day option to purchase up to an additional 765,306 shares o
3 Things In Biotech, May 25: A CLL Game Changer https://seekingalpha.com/article/4177411-3-things-biotech-may-25-cll-game-changer?source=feed_sector_healthcare May 26, 2018 - AbbVie is about to change the CLL game again?Little Krystal Biotech looks to attack epidermolysis bullosa.CytomX allowed to unleash its probody drug conjugate on cancer.
CytomX: X Marks The Spot Of Reversal https://seekingalpha.com/article/4175670-cytomx-x-marks-spot-reversal?source=feed_sector_healthcare May 20, 2018 - CytomX bounced wonderfully off its 200-day MA.Their presentation at ASCO was well-received.CytomX is a momentum stock that appears well-positioned for additional appreciation.Now is probably a prudent
CytomX Therapeutics (CTMX) Presents At Bank Of America Merrill Lynch 2018 Healthcare Conference - Slideshow https://seekingalpha.com/article/4175462-cytomx-therapeutics-ctmx-presents-bank-america-merrill-lynch-2018-healthcare-conference?source=feed_sector_healthcare May 18, 2018 - The following slide deck was published by CytomX Therapeutics in conjunction with this event.
ImmunoGen: An Extremely Promising ADC Therapeutic Innovator https://seekingalpha.com/article/4171596-immunogen-extremely-promising-adc-therapeutic-innovator?source=feed_sector_healthcare May 09, 2018 - ImmunoGen is powering a highly enriched pipeline of antibody conjugate drug (“ADC”) for the stellar cancer treatment. ADC enables the efficient killing of cancer cells while minimizing the toxic effec

Pages: 123456

Page 1>

Related Companies

Name Exchange Price Mkt Cap
CARA Cara Therapeutics, Inc. NASDAQ $21.19 $832.56M
AMRN Amarin Corporation plc NASDAQ $2.83 $838.67M
AMPH Amphastar Pharmaceuticals, Inc. NASDAQ $18.33 $847.88M
RDUS Radius Health, Inc. NASDAQ $17.78 $808.57M
RVNC Revance Therapeutics, Inc. NASDAQ $23.5001 $868.04M
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for CytomX Therapeutics
CTMX - Google Finance https://www.google.com/finance?q=CTMX Industry related info and international coverage Summary News
CTMX - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=CTMX Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options